X4 Pharmaceuticals (XFOR) Stock: Buy, Sell, or Hold?
XFOR - X4 Pharmaceuticals, Inc. Common Stock
$3.17
-0.18 (-5.37%)
▼
5d:
-2.46%
30d:
+9.31%
90d:
-23.61%
WAIT
LOW Confidence
Analysis Updated: Nov 3, 2026 12:00 AM ET
Earnings: Nov 04, 2026
0d
Get Alerted When XFOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: XFOR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: XFOR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: XFOR is currently trading at $3.17, which is considered extended relative to its 30-day fair value range of $2.71 to $3.24.
Technical Outlook: Technically, XFOR is in a strong downtrend. Immediate support is located at $2.88, while resistance sits at $3.49. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: XFOR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.60 (+265.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XFOR is in a strong downtrend. Immediate support is located at $2.88, while resistance sits at $3.49. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: XFOR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.60 (+265.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.71 -
$3.24
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 265.9% below Wall St target ($11.60)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.71 -
$3.24
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.88
Resistance Level
$3.49
Current Trend
Strong Downtrend
Technical data as of
Nov 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.13
Wall Street Target
$11.60
(+265.9%)
Revenue Growth (YoY)
346.3%
Share & Embed Analysis
Last updated: November 03, 2026 10:45 PM ET
Data refreshes hourly during market hours. Next update: 11:45 PM
Data refreshes hourly during market hours. Next update: 11:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XFOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 50 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$278 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$107 | 41 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$68 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$131 | 53 HOLD |
